Replies to post #285300 on Naz News, Gappers and FLE''s

[iconoclassic]

NEOP not holding the AH gain, 4.65 rtq ...... NEOP Neoprobe Corporation announces Lymphoseek meets all endpoints in NEO3-09 Phase 3 study (5.07 +0.13)

Co announces top-line results from its Lymphoseek (tilmanocept) NEO3-09 study. The NEO3-09 study met all primary and secondary endpoints and highlighted the superior performance by Lymphoseek compared to vital blue dye in intraoperative lymphatic mapping, a procedure in which lymph nodes are identified for biopsy to assess for the presence of tumor. The NEO3-09 Phase 3 clinical study, the Company's second successful Phase 3 study for Lymphoseek, enrolled over 150 subjects with either breast cancer or melanoma within the intent-to-treat population. Lymphoseek performed equally well in both cancer types. As previously disclosed by the Company, the full NEO3-09 data set will be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology, June 3-7, in Chicago.